Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 8:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Healthy Adult Volunteers
Interventions: BMS-986120, Placebo, Midazolam; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: GNS-3545, GNS-3545 Placebo; Drug
Lead sponsor: Genosco Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: INS1007, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: TT-01025-CL; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Enteritis Caused by Radiation
Interventions: SYN-020 Delayed Release Capsule; Drug
Lead sponsor: Theriva Biologics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Infections, Respiratory Tract
Interventions: GSK1325756 Solution, GSK1325756 Solution Matching Placebo, GSK1325756 Tablet, GSK1325756 Tablet Matching Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Autoimmune Diseases
Interventions: CBP-307, Placebo-matched CBP-307, Moxifloxacin (Avelox), Placebo-matched Moxifloxacin; Drug
Lead sponsor: Connect Biopharma Australia Pty Ltd; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Coccidioidomycosis
Interventions: Placebo, VT-1598; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Malaria, Vivax
Interventions: Tafenoquine 300mg, Tafenoquine 600mg, Tafenoquine 1200mg, moxifloxacin, Placebo for Tafenoquine, Placebo for moxifloxaxin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Culver City, California • Baltimore, Maryland

Conditions: Chronic Pain, Nociceptive Pain
Interventions: CNTX-6970, Placebo; Drug · Other
Lead sponsor: Centrexion Therapeutics; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Type 2 Diabetes Mellitus
Interventions: DS-1150b, Placebo; Drug · Other
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Meningitis, Meningococcal
Interventions: rLP2086 vaccine, control; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 5,715 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 39
States / cities: Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 28 more

Conditions: Hyperuricemia, Gout, Qt Interval, Variation in
Interventions: LC350189 200mg, Placebo, Moxifloxacin 400mg, LC350189 600mg; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cranial Waveform in Normal Patients as a Result of Cardiac Cycle, Healthy
Interventions: Harmony Headset; Device
Lead sponsor: MindRhythm, Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Cupertino, California

Conditions: Stroke, Stroke, Acute, Stroke, Ischemic
Interventions: AER-271, Placebo; Drug
Lead sponsor: Aeromics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Severe Persistent Asthma
Interventions: Bronchoscopy; Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Volunteer
Interventions: Not listed
Lead sponsor: Biogen; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 246 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: Baltimore, Maryland • St Louis, Missouri • Rochester, New York + 1 more

Conditions: Ulcerative Colitis
Interventions: BBT-401-1S, Single dose, BBT-401-1S, Multiple doses, Placebo; Drug
Lead sponsor: Bridge Biotherapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: PUL-042 Inhalation Solution; Drug
Lead sponsor: Pulmotect, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Subjects
Interventions: MT-7117, moxifloxacin, Placebo; Drug
Lead sponsor: Tanabe Pharma America, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Malaria
Interventions: PfSPZ Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Baltimore, Maryland • Bethesda, Maryland

Conditions: Inflammatory Bowel Disease
Interventions: E6007; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Type 1 Diabetes
Interventions: Measurement of vascular function per SphymgnoCor equipment; Procedure
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 12 Years to 14 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Healthy
Interventions: BBP-711, Placebo; Drug
Lead sponsor: Cantero Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tempe, Arizona

Search by objective public record fields.

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120

A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants

A Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of TT-01025-CL in Healthy Subjects

Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered SYN 020

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects

A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects

Safety and Pharmacokinetics of VT-1598

Tafenoquine Thorough QTc Study in Healthy Subjects

A Placebo-Controlled, Two-Part Study, Oral Dose to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CNTX-6970 in Healthy Subjects

Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects

500 "Normal" Adult Subjects Who Have Experienced no Known Brain Injury Will Participate in Collecting Data That Will Assist With the Optimization of the Diagnostic Capabilities of the Harmony in Detecting Neurologic Abnormalities.

Phase 1 Study to Assess AER-271

Bronchoscopy Study for Severe Asthma

MS PATHS Normative Sub-Study

First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers

Safety and Tolerability of Single Ascending Doses of PUL-042 Inhalation Solution in Healthy Subjects

Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults

A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects

Vascular Function in Adolescent, Diabetic Children

A Study of BBP-711 (ORF-229) in Healthy Adult Volunteers